The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global β-Lactamaseinhibitors Market Research Report 2025
Synopsis
Beta-lactams are the antibiotics that contain intramecyclic amines in their molecules, including penicillin and cephalosporin.In recent years, the development of - lactamase inhibitors, oxyspora, thiomycin and so on.
The global β-Lactamaseinhibitors market was valued at US$ 28330 million in 2023 and is anticipated to reach US$ 34510 million by 2030, witnessing a CAGR of 2.9% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for β-Lactamaseinhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding β-Lactamaseinhibitors.
Report Scope
The β-Lactamaseinhibitors market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global β-Lactamaseinhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the β-Lactamaseinhibitors companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GSK
Pfizer
Johnson & Johnson
Bayer HealthCare
Abbot Laboratories
Roche Pharmaceuticals
Sanofi Aventis
Takeda Pharmaceutical Company
Toyama Chemical
Merck
Choongwae
Ranbaxy
Yungjin
Sumitomo Dainippon
CSPC
Shanghai Sine Pharmaceutical Laboratories (Shanghai Pharmaceuticals Holding)
CTTQ
Sinopharm
HISUN PHARMACEUTICAL
Segment by Type
Tablets
Capsule
Granules
Injection
Segment by Application
Hospital
Clinic
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of β-Lactamaseinhibitors companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Beta-lactams are the antibiotics that contain intramecyclic amines in their molecules, including penicillin and cephalosporin.In recent years, the development of - lactamase inhibitors, oxyspora, thiomycin and so on.
The global β-Lactamaseinhibitors market was valued at US$ 28330 million in 2023 and is anticipated to reach US$ 34510 million by 2030, witnessing a CAGR of 2.9% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for β-Lactamaseinhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding β-Lactamaseinhibitors.
Report Scope
The β-Lactamaseinhibitors market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global β-Lactamaseinhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the β-Lactamaseinhibitors companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GSK
Pfizer
Johnson & Johnson
Bayer HealthCare
Abbot Laboratories
Roche Pharmaceuticals
Sanofi Aventis
Takeda Pharmaceutical Company
Toyama Chemical
Merck
Choongwae
Ranbaxy
Yungjin
Sumitomo Dainippon
CSPC
Shanghai Sine Pharmaceutical Laboratories (Shanghai Pharmaceuticals Holding)
CTTQ
Sinopharm
HISUN PHARMACEUTICAL
Segment by Type
Tablets
Capsule
Granules
Injection
Segment by Application
Hospital
Clinic
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of β-Lactamaseinhibitors companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global β-Lactamaseinhibitors Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Tablets
1.2.3 Capsule
1.2.4 Granules
1.2.5 Injection
1.3 Market by Application
1.3.1 Global β-Lactamaseinhibitors Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global β-Lactamaseinhibitors Market Perspective (2019-2030)
2.2 β-Lactamaseinhibitors Growth Trends by Region
2.2.1 Global β-Lactamaseinhibitors Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 β-Lactamaseinhibitors Historic Market Size by Region (2019-2024)
2.2.3 β-Lactamaseinhibitors Forecasted Market Size by Region (2025-2030)
2.3 β-Lactamaseinhibitors Market Dynamics
2.3.1 β-Lactamaseinhibitors Industry Trends
2.3.2 β-Lactamaseinhibitors Market Drivers
2.3.3 β-Lactamaseinhibitors Market Challenges
2.3.4 β-Lactamaseinhibitors Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top β-Lactamaseinhibitors Players by Revenue
3.1.1 Global Top β-Lactamaseinhibitors Players by Revenue (2019-2024)
3.1.2 Global β-Lactamaseinhibitors Revenue Market Share by Players (2019-2024)
3.2 Global β-Lactamaseinhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by β-Lactamaseinhibitors Revenue
3.4 Global β-Lactamaseinhibitors Market Concentration Ratio
3.4.1 Global β-Lactamaseinhibitors Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by β-Lactamaseinhibitors Revenue in 2023
3.5 β-Lactamaseinhibitors Key Players Head office and Area Served
3.6 Key Players β-Lactamaseinhibitors Product Solution and Service
3.7 Date of Enter into β-Lactamaseinhibitors Market
3.8 Mergers & Acquisitions, Expansion Plans
4 β-Lactamaseinhibitors Breakdown Data by Type
4.1 Global β-Lactamaseinhibitors Historic Market Size by Type (2019-2024)
4.2 Global β-Lactamaseinhibitors Forecasted Market Size by Type (2025-2030)
5 β-Lactamaseinhibitors Breakdown Data by Application
5.1 Global β-Lactamaseinhibitors Historic Market Size by Application (2019-2024)
5.2 Global β-Lactamaseinhibitors Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America β-Lactamaseinhibitors Market Size (2019-2030)
6.2 North America β-Lactamaseinhibitors Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America β-Lactamaseinhibitors Market Size by Country (2019-2024)
6.4 North America β-Lactamaseinhibitors Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe β-Lactamaseinhibitors Market Size (2019-2030)
7.2 Europe β-Lactamaseinhibitors Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe β-Lactamaseinhibitors Market Size by Country (2019-2024)
7.4 Europe β-Lactamaseinhibitors Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific β-Lactamaseinhibitors Market Size (2019-2030)
8.2 Asia-Pacific β-Lactamaseinhibitors Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific β-Lactamaseinhibitors Market Size by Region (2019-2024)
8.4 Asia-Pacific β-Lactamaseinhibitors Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America β-Lactamaseinhibitors Market Size (2019-2030)
9.2 Latin America β-Lactamaseinhibitors Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America β-Lactamaseinhibitors Market Size by Country (2019-2024)
9.4 Latin America β-Lactamaseinhibitors Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa β-Lactamaseinhibitors Market Size (2019-2030)
10.2 Middle East & Africa β-Lactamaseinhibitors Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa β-Lactamaseinhibitors Market Size by Country (2019-2024)
10.4 Middle East & Africa β-Lactamaseinhibitors Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GSK
11.1.1 GSK Company Detail
11.1.2 GSK Business Overview
11.1.3 GSK β-Lactamaseinhibitors Introduction
11.1.4 GSK Revenue in β-Lactamaseinhibitors Business (2019-2024)
11.1.5 GSK Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Detail
11.2.2 Pfizer Business Overview
11.2.3 Pfizer β-Lactamaseinhibitors Introduction
11.2.4 Pfizer Revenue in β-Lactamaseinhibitors Business (2019-2024)
11.2.5 Pfizer Recent Development
11.3 Johnson & Johnson
11.3.1 Johnson & Johnson Company Detail
11.3.2 Johnson & Johnson Business Overview
11.3.3 Johnson & Johnson β-Lactamaseinhibitors Introduction
11.3.4 Johnson & Johnson Revenue in β-Lactamaseinhibitors Business (2019-2024)
11.3.5 Johnson & Johnson Recent Development
11.4 Bayer HealthCare
11.4.1 Bayer HealthCare Company Detail
11.4.2 Bayer HealthCare Business Overview
11.4.3 Bayer HealthCare β-Lactamaseinhibitors Introduction
11.4.4 Bayer HealthCare Revenue in β-Lactamaseinhibitors Business (2019-2024)
11.4.5 Bayer HealthCare Recent Development
11.5 Abbot Laboratories
11.5.1 Abbot Laboratories Company Detail
11.5.2 Abbot Laboratories Business Overview
11.5.3 Abbot Laboratories β-Lactamaseinhibitors Introduction
11.5.4 Abbot Laboratories Revenue in β-Lactamaseinhibitors Business (2019-2024)
11.5.5 Abbot Laboratories Recent Development
11.6 Roche Pharmaceuticals
11.6.1 Roche Pharmaceuticals Company Detail
11.6.2 Roche Pharmaceuticals Business Overview
11.6.3 Roche Pharmaceuticals β-Lactamaseinhibitors Introduction
11.6.4 Roche Pharmaceuticals Revenue in β-Lactamaseinhibitors Business (2019-2024)
11.6.5 Roche Pharmaceuticals Recent Development
11.7 Sanofi Aventis
11.7.1 Sanofi Aventis Company Detail
11.7.2 Sanofi Aventis Business Overview
11.7.3 Sanofi Aventis β-Lactamaseinhibitors Introduction
11.7.4 Sanofi Aventis Revenue in β-Lactamaseinhibitors Business (2019-2024)
11.7.5 Sanofi Aventis Recent Development
11.8 Takeda Pharmaceutical Company
11.8.1 Takeda Pharmaceutical Company Company Detail
11.8.2 Takeda Pharmaceutical Company Business Overview
11.8.3 Takeda Pharmaceutical Company β-Lactamaseinhibitors Introduction
11.8.4 Takeda Pharmaceutical Company Revenue in β-Lactamaseinhibitors Business (2019-2024)
11.8.5 Takeda Pharmaceutical Company Recent Development
11.9 Toyama Chemical
11.9.1 Toyama Chemical Company Detail
11.9.2 Toyama Chemical Business Overview
11.9.3 Toyama Chemical β-Lactamaseinhibitors Introduction
11.9.4 Toyama Chemical Revenue in β-Lactamaseinhibitors Business (2019-2024)
11.9.5 Toyama Chemical Recent Development
11.10 Merck
11.10.1 Merck Company Detail
11.10.2 Merck Business Overview
11.10.3 Merck β-Lactamaseinhibitors Introduction
11.10.4 Merck Revenue in β-Lactamaseinhibitors Business (2019-2024)
11.10.5 Merck Recent Development
11.11 Choongwae
11.11.1 Choongwae Company Detail
11.11.2 Choongwae Business Overview
11.11.3 Choongwae β-Lactamaseinhibitors Introduction
11.11.4 Choongwae Revenue in β-Lactamaseinhibitors Business (2019-2024)
11.11.5 Choongwae Recent Development
11.12 Ranbaxy
11.12.1 Ranbaxy Company Detail
11.12.2 Ranbaxy Business Overview
11.12.3 Ranbaxy β-Lactamaseinhibitors Introduction
11.12.4 Ranbaxy Revenue in β-Lactamaseinhibitors Business (2019-2024)
11.12.5 Ranbaxy Recent Development
11.13 Yungjin
11.13.1 Yungjin Company Detail
11.13.2 Yungjin Business Overview
11.13.3 Yungjin β-Lactamaseinhibitors Introduction
11.13.4 Yungjin Revenue in β-Lactamaseinhibitors Business (2019-2024)
11.13.5 Yungjin Recent Development
11.14 Sumitomo Dainippon
11.14.1 Sumitomo Dainippon Company Detail
11.14.2 Sumitomo Dainippon Business Overview
11.14.3 Sumitomo Dainippon β-Lactamaseinhibitors Introduction
11.14.4 Sumitomo Dainippon Revenue in β-Lactamaseinhibitors Business (2019-2024)
11.14.5 Sumitomo Dainippon Recent Development
11.15 CSPC
11.15.1 CSPC Company Detail
11.15.2 CSPC Business Overview
11.15.3 CSPC β-Lactamaseinhibitors Introduction
11.15.4 CSPC Revenue in β-Lactamaseinhibitors Business (2019-2024)
11.15.5 CSPC Recent Development
11.16 Shanghai Sine Pharmaceutical Laboratories (Shanghai Pharmaceuticals Holding)
11.16.1 Shanghai Sine Pharmaceutical Laboratories (Shanghai Pharmaceuticals Holding) Company Detail
11.16.2 Shanghai Sine Pharmaceutical Laboratories (Shanghai Pharmaceuticals Holding) Business Overview
11.16.3 Shanghai Sine Pharmaceutical Laboratories (Shanghai Pharmaceuticals Holding) β-Lactamaseinhibitors Introduction
11.16.4 Shanghai Sine Pharmaceutical Laboratories (Shanghai Pharmaceuticals Holding) Revenue in β-Lactamaseinhibitors Business (2019-2024)
11.16.5 Shanghai Sine Pharmaceutical Laboratories (Shanghai Pharmaceuticals Holding) Recent Development
11.17 CTTQ
11.17.1 CTTQ Company Detail
11.17.2 CTTQ Business Overview
11.17.3 CTTQ β-Lactamaseinhibitors Introduction
11.17.4 CTTQ Revenue in β-Lactamaseinhibitors Business (2019-2024)
11.17.5 CTTQ Recent Development
11.18 Sinopharm
11.18.1 Sinopharm Company Detail
11.18.2 Sinopharm Business Overview
11.18.3 Sinopharm β-Lactamaseinhibitors Introduction
11.18.4 Sinopharm Revenue in β-Lactamaseinhibitors Business (2019-2024)
11.18.5 Sinopharm Recent Development
11.19 HISUN PHARMACEUTICAL
11.19.1 HISUN PHARMACEUTICAL Company Detail
11.19.2 HISUN PHARMACEUTICAL Business Overview
11.19.3 HISUN PHARMACEUTICAL β-Lactamaseinhibitors Introduction
11.19.4 HISUN PHARMACEUTICAL Revenue in β-Lactamaseinhibitors Business (2019-2024)
11.19.5 HISUN PHARMACEUTICAL Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global β-Lactamaseinhibitors Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Tablets
Table 3. Key Players of Capsule
Table 4. Key Players of Granules
Table 5. Key Players of Injection
Table 6. Global β-Lactamaseinhibitors Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global β-Lactamaseinhibitors Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global β-Lactamaseinhibitors Market Size by Region (2019-2024) & (US$ Million)
Table 9. Global β-Lactamaseinhibitors Market Share by Region (2019-2024)
Table 10. Global β-Lactamaseinhibitors Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 11. Global β-Lactamaseinhibitors Market Share by Region (2025-2030)
Table 12. β-Lactamaseinhibitors Market Trends
Table 13. β-Lactamaseinhibitors Market Drivers
Table 14. β-Lactamaseinhibitors Market Challenges
Table 15. β-Lactamaseinhibitors Market Restraints
Table 16. Global β-Lactamaseinhibitors Revenue by Players (2019-2024) & (US$ Million)
Table 17. Global β-Lactamaseinhibitors Market Share by Players (2019-2024)
Table 18. Global Top β-Lactamaseinhibitors Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in β-Lactamaseinhibitors as of 2023)
Table 19. Ranking of Global Top β-Lactamaseinhibitors Companies by Revenue (US$ Million) in 2023
Table 20. Global 5 Largest Players Market Share by β-Lactamaseinhibitors Revenue (CR5 and HHI) & (2019-2024)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players β-Lactamaseinhibitors Product Solution and Service
Table 23. Date of Enter into β-Lactamaseinhibitors Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global β-Lactamaseinhibitors Market Size by Type (2019-2024) & (US$ Million)
Table 26. Global β-Lactamaseinhibitors Revenue Market Share by Type (2019-2024)
Table 27. Global β-Lactamaseinhibitors Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 28. Global β-Lactamaseinhibitors Revenue Market Share by Type (2025-2030)
Table 29. Global β-Lactamaseinhibitors Market Size by Application (2019-2024) & (US$ Million)
Table 30. Global β-Lactamaseinhibitors Revenue Market Share by Application (2019-2024)
Table 31. Global β-Lactamaseinhibitors Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 32. Global β-Lactamaseinhibitors Revenue Market Share by Application (2025-2030)
Table 33. North America β-Lactamaseinhibitors Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 34. North America β-Lactamaseinhibitors Market Size by Country (2019-2024) & (US$ Million)
Table 35. North America β-Lactamaseinhibitors Market Size by Country (2025-2030) & (US$ Million)
Table 36. Europe β-Lactamaseinhibitors Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. Europe β-Lactamaseinhibitors Market Size by Country (2019-2024) & (US$ Million)
Table 38. Europe β-Lactamaseinhibitors Market Size by Country (2025-2030) & (US$ Million)
Table 39. Asia-Pacific β-Lactamaseinhibitors Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 40. Asia-Pacific β-Lactamaseinhibitors Market Size by Region (2019-2024) & (US$ Million)
Table 41. Asia-Pacific β-Lactamaseinhibitors Market Size by Region (2025-2030) & (US$ Million)
Table 42. Latin America β-Lactamaseinhibitors Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Latin America β-Lactamaseinhibitors Market Size by Country (2019-2024) & (US$ Million)
Table 44. Latin America β-Lactamaseinhibitors Market Size by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa β-Lactamaseinhibitors Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Middle East & Africa β-Lactamaseinhibitors Market Size by Country (2019-2024) & (US$ Million)
Table 47. Middle East & Africa β-Lactamaseinhibitors Market Size by Country (2025-2030) & (US$ Million)
Table 48. GSK Company Detail
Table 49. GSK Business Overview
Table 50. GSK β-Lactamaseinhibitors Product
Table 51. GSK Revenue in β-Lactamaseinhibitors Business (2019-2024) & (US$ Million)
Table 52. GSK Recent Development
Table 53. Pfizer Company Detail
Table 54. Pfizer Business Overview
Table 55. Pfizer β-Lactamaseinhibitors Product
Table 56. Pfizer Revenue in β-Lactamaseinhibitors Business (2019-2024) & (US$ Million)
Table 57. Pfizer Recent Development
Table 58. Johnson & Johnson Company Detail
Table 59. Johnson & Johnson Business Overview
Table 60. Johnson & Johnson β-Lactamaseinhibitors Product
Table 61. Johnson & Johnson Revenue in β-Lactamaseinhibitors Business (2019-2024) & (US$ Million)
Table 62. Johnson & Johnson Recent Development
Table 63. Bayer HealthCare Company Detail
Table 64. Bayer HealthCare Business Overview
Table 65. Bayer HealthCare β-Lactamaseinhibitors Product
Table 66. Bayer HealthCare Revenue in β-Lactamaseinhibitors Business (2019-2024) & (US$ Million)
Table 67. Bayer HealthCare Recent Development
Table 68. Abbot Laboratories Company Detail
Table 69. Abbot Laboratories Business Overview
Table 70. Abbot Laboratories β-Lactamaseinhibitors Product
Table 71. Abbot Laboratories Revenue in β-Lactamaseinhibitors Business (2019-2024) & (US$ Million)
Table 72. Abbot Laboratories Recent Development
Table 73. Roche Pharmaceuticals Company Detail
Table 74. Roche Pharmaceuticals Business Overview
Table 75. Roche Pharmaceuticals β-Lactamaseinhibitors Product
Table 76. Roche Pharmaceuticals Revenue in β-Lactamaseinhibitors Business (2019-2024) & (US$ Million)
Table 77. Roche Pharmaceuticals Recent Development
Table 78. Sanofi Aventis Company Detail
Table 79. Sanofi Aventis Business Overview
Table 80. Sanofi Aventis β-Lactamaseinhibitors Product
Table 81. Sanofi Aventis Revenue in β-Lactamaseinhibitors Business (2019-2024) & (US$ Million)
Table 82. Sanofi Aventis Recent Development
Table 83. Takeda Pharmaceutical Company Company Detail
Table 84. Takeda Pharmaceutical Company Business Overview
Table 85. Takeda Pharmaceutical Company β-Lactamaseinhibitors Product
Table 86. Takeda Pharmaceutical Company Revenue in β-Lactamaseinhibitors Business (2019-2024) & (US$ Million)
Table 87. Takeda Pharmaceutical Company Recent Development
Table 88. Toyama Chemical Company Detail
Table 89. Toyama Chemical Business Overview
Table 90. Toyama Chemical β-Lactamaseinhibitors Product
Table 91. Toyama Chemical Revenue in β-Lactamaseinhibitors Business (2019-2024) & (US$ Million)
Table 92. Toyama Chemical Recent Development
Table 93. Merck Company Detail
Table 94. Merck Business Overview
Table 95. Merck β-Lactamaseinhibitors Product
Table 96. Merck Revenue in β-Lactamaseinhibitors Business (2019-2024) & (US$ Million)
Table 97. Merck Recent Development
Table 98. Choongwae Company Detail
Table 99. Choongwae Business Overview
Table 100. Choongwae β-Lactamaseinhibitors Product
Table 101. Choongwae Revenue in β-Lactamaseinhibitors Business (2019-2024) & (US$ Million)
Table 102. Choongwae Recent Development
Table 103. Ranbaxy Company Detail
Table 104. Ranbaxy Business Overview
Table 105. Ranbaxy β-Lactamaseinhibitors Product
Table 106. Ranbaxy Revenue in β-Lactamaseinhibitors Business (2019-2024) & (US$ Million)
Table 107. Ranbaxy Recent Development
Table 108. Yungjin Company Detail
Table 109. Yungjin Business Overview
Table 110. Yungjin β-Lactamaseinhibitors Product
Table 111. Yungjin Revenue in β-Lactamaseinhibitors Business (2019-2024) & (US$ Million)
Table 112. Yungjin Recent Development
Table 113. Sumitomo Dainippon Company Detail
Table 114. Sumitomo Dainippon Business Overview
Table 115. Sumitomo Dainippon β-Lactamaseinhibitors Product
Table 116. Sumitomo Dainippon Revenue in β-Lactamaseinhibitors Business (2019-2024) & (US$ Million)
Table 117. Sumitomo Dainippon Recent Development
Table 118. CSPC Company Detail
Table 119. CSPC Business Overview
Table 120. CSPC β-Lactamaseinhibitors Product
Table 121. CSPC Revenue in β-Lactamaseinhibitors Business (2019-2024) & (US$ Million)
Table 122. CSPC Recent Development
Table 123. Shanghai Sine Pharmaceutical Laboratories (Shanghai Pharmaceuticals Holding) Company Detail
Table 124. Shanghai Sine Pharmaceutical Laboratories (Shanghai Pharmaceuticals Holding) Business Overview
Table 125. Shanghai Sine Pharmaceutical Laboratories (Shanghai Pharmaceuticals Holding) β-Lactamaseinhibitors Product
Table 126. Shanghai Sine Pharmaceutical Laboratories (Shanghai Pharmaceuticals Holding) Revenue in β-Lactamaseinhibitors Business (2019-2024) & (US$ Million)
Table 127. Shanghai Sine Pharmaceutical Laboratories (Shanghai Pharmaceuticals Holding) Recent Development
Table 128. CTTQ Company Detail
Table 129. CTTQ Business Overview
Table 130. CTTQ β-Lactamaseinhibitors Product
Table 131. CTTQ Revenue in β-Lactamaseinhibitors Business (2019-2024) & (US$ Million)
Table 132. CTTQ Recent Development
Table 133. Sinopharm Company Detail
Table 134. Sinopharm Business Overview
Table 135. Sinopharm β-Lactamaseinhibitors Product
Table 136. Sinopharm Revenue in β-Lactamaseinhibitors Business (2019-2024) & (US$ Million)
Table 137. Sinopharm Recent Development
Table 138. HISUN PHARMACEUTICAL Company Detail
Table 139. HISUN PHARMACEUTICAL Business Overview
Table 140. HISUN PHARMACEUTICAL β-Lactamaseinhibitors Product
Table 141. HISUN PHARMACEUTICAL Revenue in β-Lactamaseinhibitors Business (2019-2024) & (US$ Million)
Table 142. HISUN PHARMACEUTICAL Recent Development
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources
List of Figures
Figure 1. Global β-Lactamaseinhibitors Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global β-Lactamaseinhibitors Market Share by Type: 2023 VS 2030
Figure 3. Tablets Features
Figure 4. Capsule Features
Figure 5. Granules Features
Figure 6. Injection Features
Figure 7. Global β-Lactamaseinhibitors Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global β-Lactamaseinhibitors Market Share by Application: 2023 VS 2030
Figure 9. Hospital Case Studies
Figure 10. Clinic Case Studies
Figure 11. Other Case Studies
Figure 12. β-Lactamaseinhibitors Report Years Considered
Figure 13. Global β-Lactamaseinhibitors Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 14. Global β-Lactamaseinhibitors Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global β-Lactamaseinhibitors Market Share by Region: 2023 VS 2030
Figure 16. Global β-Lactamaseinhibitors Market Share by Players in 2023
Figure 17. Global Top β-Lactamaseinhibitors Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in β-Lactamaseinhibitors as of 2023)
Figure 18. The Top 10 and 5 Players Market Share by β-Lactamaseinhibitors Revenue in 2023
Figure 19. North America β-Lactamaseinhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. North America β-Lactamaseinhibitors Market Share by Country (2019-2030)
Figure 21. United States β-Lactamaseinhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Canada β-Lactamaseinhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe β-Lactamaseinhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe β-Lactamaseinhibitors Market Share by Country (2019-2030)
Figure 25. Germany β-Lactamaseinhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. France β-Lactamaseinhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. U.K. β-Lactamaseinhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Italy β-Lactamaseinhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Russia β-Lactamaseinhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Nordic Countries β-Lactamaseinhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific β-Lactamaseinhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific β-Lactamaseinhibitors Market Share by Region (2019-2030)
Figure 33. China β-Lactamaseinhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Japan β-Lactamaseinhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. South Korea β-Lactamaseinhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Southeast Asia β-Lactamaseinhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. India β-Lactamaseinhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Australia β-Lactamaseinhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America β-Lactamaseinhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America β-Lactamaseinhibitors Market Share by Country (2019-2030)
Figure 41. Mexico β-Lactamaseinhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Brazil β-Lactamaseinhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa β-Lactamaseinhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa β-Lactamaseinhibitors Market Share by Country (2019-2030)
Figure 45. Turkey β-Lactamaseinhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Saudi Arabia β-Lactamaseinhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. GSK Revenue Growth Rate in β-Lactamaseinhibitors Business (2019-2024)
Figure 48. Pfizer Revenue Growth Rate in β-Lactamaseinhibitors Business (2019-2024)
Figure 49. Johnson & Johnson Revenue Growth Rate in β-Lactamaseinhibitors Business (2019-2024)
Figure 50. Bayer HealthCare Revenue Growth Rate in β-Lactamaseinhibitors Business (2019-2024)
Figure 51. Abbot Laboratories Revenue Growth Rate in β-Lactamaseinhibitors Business (2019-2024)
Figure 52. Roche Pharmaceuticals Revenue Growth Rate in β-Lactamaseinhibitors Business (2019-2024)
Figure 53. Sanofi Aventis Revenue Growth Rate in β-Lactamaseinhibitors Business (2019-2024)
Figure 54. Takeda Pharmaceutical Company Revenue Growth Rate in β-Lactamaseinhibitors Business (2019-2024)
Figure 55. Toyama Chemical Revenue Growth Rate in β-Lactamaseinhibitors Business (2019-2024)
Figure 56. Merck Revenue Growth Rate in β-Lactamaseinhibitors Business (2019-2024)
Figure 57. Choongwae Revenue Growth Rate in β-Lactamaseinhibitors Business (2019-2024)
Figure 58. Ranbaxy Revenue Growth Rate in β-Lactamaseinhibitors Business (2019-2024)
Figure 59. Yungjin Revenue Growth Rate in β-Lactamaseinhibitors Business (2019-2024)
Figure 60. Sumitomo Dainippon Revenue Growth Rate in β-Lactamaseinhibitors Business (2019-2024)
Figure 61. CSPC Revenue Growth Rate in β-Lactamaseinhibitors Business (2019-2024)
Figure 62. Shanghai Sine Pharmaceutical Laboratories (Shanghai Pharmaceuticals Holding) Revenue Growth Rate in β-Lactamaseinhibitors Business (2019-2024)
Figure 63. CTTQ Revenue Growth Rate in β-Lactamaseinhibitors Business (2019-2024)
Figure 64. Sinopharm Revenue Growth Rate in β-Lactamaseinhibitors Business (2019-2024)
Figure 65. HISUN PHARMACEUTICAL Revenue Growth Rate in β-Lactamaseinhibitors Business (2019-2024)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
